Immusoft Pipeline

Immusoft is advancing engineered B cell therapies across rare disease and high-prevalence indications. By leveraging our Immune System Programming (ISP™) platform, we believe that we can develop therapeutics with the potential to deliver meaningful functional improvements for patients.

We have a broad pipeline, with our lead program in MPS I (Mucopolysaccharidosis type I), and preclinical programs in rare diseases and other indications with significant unmet need.

  • ISP-001

    MPS I

    Discovery IND-Enabling Phase 1/2a Pivotal
  • ISP-002

    MPS II

    Discovery IND-Enabling Phase 1/2a Pivotal
  • Gaucher

    Discovery IND-Enabling Phase 1/2a Pivotal
  • Parkinson’s

    Partnering Target
    Discovery IND-Enabling Phase 1/2a Pivotal
  • Obesity / Diabetes

    Partnering Target
    Discovery IND-Enabling Phase 1/2a Pivotal
  • Oncology

    Partnering Target
    Discovery IND-Enabling Phase 1/2a Pivotal
  • Autoimmune

    Partnering Target
    Discovery IND-Enabling Phase 1/2a Pivotal